MARKETING AUDIT OF UKRAINIAN PHARMACEUTICAL MARKET FOR LOCAL TREATMENT ACNE AND DEMODICOSIS

2020 ◽  
Vol 73 (11) ◽  
pp. 2482-2488
Author(s):  
Alina S. Koval ◽  
Lena L. Davtian ◽  
Anna A. Drozdova ◽  
Liudmyla A. Naumova
Keyword(s):  
Benzoyl Peroxide ◽  
Low Cost ◽  
Local Treatment ◽  
Pharmaceutical Market ◽  
State Register ◽  
Observation Methods ◽  
Audit Data ◽  
Expert Center ◽  
Soft Drugs ◽  
Marketing Methods

The aim: To conduct a marketing audit of the pharmaceutical market of Ukraine for acne and demodicosis medications. Materials and methods: The study used marketing methods of analysis, survey, observation methods and reference literature – State Register of Medicines of Ukraine of the State Expert Center of the Ministry of Health of Ukraine. Results: As a result of marketing audit of retail audit data of pharmacy sales revealed that the leading sales in packaging is MNL benzylbenzoate, the share of which reached in different years from 45% to 32%, which was 1380902 and 647576 packages per year, respectively, in second place – metronidazole , benzoyl peroxide, zinc ointment and sulfur ointment respectively. Conclusions: According to our analysis, it has been found that the highest sales volume (in packs) are of the low-cost brands, which are the most economically available and have the most effective therapeutic effect. Therefore, it is important to create multicomponent soft drugs in the form of cream and gel based on metronidazole, benzyl benzoate and benzoyl peroxide.

Management of skin disease

2010 ◽  
pp. 4731-4740
Author(s):  
Rod Sinclair
Keyword(s):  
Salicylic Acid ◽  
Benzoyl Peroxide ◽  
Active Ingredient ◽  
Plaque Psoriasis ◽  
Skin Disease ◽  
Topical Therapy ◽  
Local Treatment ◽  
Skin Disorders ◽  
Topical Treatments ◽  
Anti Inflammatory

Topical therapy employs a vehicle (ointments, creams, lotions, gels) to deliver an active ingredient to the skin, to provide a protective barrier, or to hydrate and moisturize the skin. There are many types of topical treatments, including (1) antipruritics, e.g. calamine, are used to relieve itching; (2) keratolytics, e.g. salicylic acid, urea, are used to remove hyperkeratotic skin; (3) tars act by reducing the thickness of the epidermis; (4) corticosteroids have anti-inflammatory and immunosuppressive effects that are useful in treating many skin disorders; (5) calcipotriol (an analogue of 1,25-dihydroxycholecalciferol) reduces epidermal proliferation and is used in local treatment of plaque psoriasis; (6) retinoids influence immune function and have some anti-inflammatory activity and are used in acne; (7) antiseptics, e.g. benzoyl peroxide, chlorhexidine; (8) antifungal agents; (9) sunscreens; (10) anaesthetics/analgesics....

scholarly journals A low-cost method for monitoring snow characteristics at remote field sites

2021 ◽  
Vol 15 (1) ◽  
pp. 1-15
Author(s):  
Rosamond J. Tutton ◽  
Robert G. Way
Keyword(s):  
Snow Depth ◽  
Low Cost ◽  
Wildlife Habitat ◽  
Daily Maximum ◽  
Natural Environments ◽  
Observation Methods ◽  
Northern Regions ◽  
Spatially Distributed ◽  
Order Of Magnitude ◽  
Cost Efficient

Abstract. The lack of spatially distributed snow depth measurements in natural environments is a challenge worldwide. These data gaps are of particular relevance in northern regions such as coastal Labrador where changes to snow conditions directly impact Indigenous livelihoods, local vegetation, permafrost distribution and wildlife habitat. This problem is exacerbated by the lack of cost-efficient and reliable snow observation methods available to researchers studying cryosphere–vegetation interactions in remote regions. We propose a new method termed snow characterization with light and temperature (SCLT) for estimating snow depth using vertically arranged multivariate (light and temperature) data loggers. To test this new approach, six snow stakes outfitted with SCLT loggers were installed in forested and tundra ecotypes in Arctic and subarctic Labrador. The results from 1 year of field measurement indicate that daily maximum light intensity (lux) at snow-covered sensors is diminished by more than an order of magnitude compared to uncovered sensors. This contrast enables differentiation between snow coverage at different sensor heights and allows for robust determination of daily snow heights throughout the year. Further validation of SCLT and the inclusion of temperature determinants is needed to resolve ambiguities with thresholds for snow detection and to elucidate the impacts of snow density on retrieved light and temperature profiles. However, the results presented in this study suggest that the proposed technique represents a significant improvement over prior methods for snow depth characterization at remote field sites in terms of practicality, simplicity and versatility.

scholarly journals Analysis of assortment and volumes of consumption of antihistamin preparations in Ukraine

2018 ◽  
pp. 12-21
Author(s):  
L.V. Iakovlieva ◽  
O. G. Berdnik ◽  
A. A. Gurtyakova
Keyword(s):  
Economic Development ◽  
Low Cost ◽  
Adult Population ◽  
Allergic Diseases ◽  
High Availability ◽  
Pharmaceutical Market ◽  
Total Consumption ◽  
Quantitative Ratio ◽  
Three Generations ◽  
The Face

Over the past 30 years, the prevalence of allergic diseases has doubled every 10 years. According to WHO, currently about 5% of the world's adult population and 15% of children suffer from allergic diseases. The purpose of the study is to analyze the assortment of antihistamines in the pharmaceutical market of Ukraine, determine the availability for consumers by the indicator of Ca.s. and their volumes of consumption by ATS/DDD-methodology during 2014‒2017. Represented in the pharmaceutical market of Ukraine antihistamines were analyzed according to the analytical system of research of the pharmaceutical market «Pharmstandard» of the company «MORION». As an indicator of socio-economic accessibility of antihistamines, an indicator of the adequacy of the solvency of Ca.s. Volumes of consumption of antihistamines were examined using the WHO recommended ATC/DDD methodology. Information on the DDD values is available on the WHO website: www.who.int/countries/ukr. During the period under study, there was a decrease in the number of TNs against the background of an increase in the number of INNs of all three generations. The quantitative ratio of domestic and foreign producers has not changed significantly. Based on the results of the Ca.s. found that antihistamines for the population of Ukraine for all four years are mainly high-availability drugs. And only 14.29% of fexofenadine preparations (in 2014) and 3.22% of desloratadine preparations (in 2015) are medium-accessible. The low indicator of the adequacy of solvency (Ca.s.) to 5%, confirms the availability of drugs group R06 and guarantees their consumption in the face of a decline in economic development in Ukraine. The most consumed during the studied four years were LS of five INNs: Mebrogroline, Cetirizine, Loratadine, Levocetirizine and Desloratadine, related to all three generations of antihistamines. Consumption of this group of the most used drugs during the study period was 89.94%, 90.64%, 90.70% and 90.47%, respectively, over the years of total consumption of antihistamines. During 2014‒2017 there is a decrease in the number of TN drugs against the background of an increase in the number of INN: from 172 TN on the basis of 16 INN in 2014 to 160 TN on the basis of 17 INNs in 2017. The quantitative ratio of domestic and foreign producers has not changed significantly. The assortment of antihistamine drugs for 2017 is quite wide. On the pharmaceutical market of Ukraine are represented drugs of all three generations. Depending on the manufacturer, the prices varied from low to high, namely the spread of prices from 1.65 UAH to 212.43 UAH in 2014 and from 4.76 UAH to 567.63 UAH in 2017, which made it possible to select individual drugs taking into account the active ingredients, dosage form and price. According to the results of the Ca.s indices, it is established that antihistamines for the population of Ukraine for the entire four years are represented mainly by high-availability TN. And only 14.29% of fexofenadine preparations (in 2014) and 3.22% of desloratadine preparations (in 2015) are medium-accessible. The low indicator of the adequacy of solvency (Ca.s.) to 5%, confirms the availability of drugs group R06 and guarantees their consumption in the face of a decline in economic development in Ukraine. According to the analysis of the consumption of antihistamines in DDDs/1000 inhabitants/day, the increase in the consumption of these drugs was observed every year from 9.64 in 2014 to 10.60 in 2017. At the same time, the consumption of the latest generation drugs increased: INN desloratadine (from 0.98 in 2014 to 1.27 in 2017) and INN levocetirizine (from 1.91 in 2014 to 2.53 in 2017), which have profitable pharmacokinetic characteristics and the optimal efficiency / safety ratio. The consumption of second-generation drugs remains stably large: loratadine (2.62 in both 2014 and 2017), cetirizine (from 1.78 in 2014 to 1.94 in 2017). Along with sufficiently high pharmacological activity, they have a relatively low cost, since they are mainly presented in the pharmaceutical market in the form of generic versions. Against the background of the trend of increasing consumption of antihistamines in Ukraine over the last four years (from 9.64 DDDs/1000 inhabitants/day in 2014 to 10.60 DDDs/1000 inhabitants/day in 2017), it is established that in Ukraine there is a large number patients who do not receive in full, or do not receive quality adequate antihistamine therapy at all.

scholarly journals Marketing Analysis: Antiemetic Drugs on the Pharmaceutical Market of Uzbekistan

2021 ◽  
Author(s):  
Samedinova Dilnoza Nuriddin qizi ◽  
Yunusova Kholida Mannanovna
Keyword(s):  
Medical Practice ◽  
Medical Devices ◽  
Medical Equipment ◽  
Dosage Forms ◽  
Pharmaceutical Market ◽  
State Register ◽  
Antiemetic Drugs ◽  
Marketing Analysis ◽  
The Republic ◽  
Audit Program

Abstract In this study, we analysed, with the help of the “State Register of Medicines, Medical Devices and Medical Equipment Permitted for Use in Medical Practice of the Republic of Uzbekistan”, the number, dosage forms and cost of registered antiemetic drugs in 2016-2020 based on the DRUG AUDIT program, which offers a database of information from 2016 to 2020.

scholarly journals Analysis of the Ukrainian pharmaceutical retail market regarding dorsalgia treatment drugs

2021 ◽  
pp. 36-44
Author(s):  
L. M. Unhurian ◽  
O. I. Bielyaieva ◽  
I.S. Yashchuk ◽  
I. B. Pietkova ◽  
T. I. Berbat
Keyword(s):  
Local Treatment ◽  
Herbal Medicines ◽  
Limited Range ◽  
Pharmaceutical Market ◽  
New Drugs ◽  
Oral Dosage ◽  
Medicinal Products ◽  
Working Age ◽  
Leading Position ◽  
Trade Names

Pharmaceutical care for treating dorsalgia is not only of medical significance, but also has a socio-economic aspect. Back pain often occurs in the working-age population. The dorsalgia treatment requires substantial economic costs and leads to deterioration in the quality of life. Aim. To analyze and systematize the official sources concerning medicines for treating dorsalgia at the domestic pharmaceutical market, as well as to determine promising directions for expanding the drug assortment. Results. The results of the study have shown that the consumption of non-steroidal anti-inflammatory drugs (NSAIDs) occupy a leading position by the volume of consumption. In Ukraine, 36 trade names (TN) of medicines with the active substance Paracetamol were registered (re-registered), including 45 % registered drugs under the brand name. The ratio of domestic and foreign NSAIDs is 56 % to 44 %; the proportion of oral dosage forms constitutes almost 50 % of the assortment. The majority of foreign medicines registered in Ukraine are manufactured in European countries, which makes up 38.9 % of the total imports of medicines. France and Great Britain occupy the leading positions in terms of supply with six THs each. The total number of drugs for external use for joint and muscle pain is 131 TH. The macro-contour of the segment of herbal medicines for treating dorsalgia at the pharmaceutical market has been formed. According to the ATX classification, the drugs studied are mostly of the pharmacotherapeutic group M02AX – Other topical products for joint and muscular pain; they are produced mainly by domestic manufacturers (60 %). More than 30 % of them are supplied by the pharmaceutical enterprise Pharmaceutical Factory Ltd. (Zhytomyr). Multi-component medicinal products of plant origin prevail significantly (66.7 %); ointments represent the broadest range (60 %). Conclusions. The limited range of drugs based on plant substances has been found; it contributes to the search for promising plant objects and the creation of new drugs based on them for the local treatment of dorsalgia. Key words: dorsalgia; medicines; herbal medicinal products; pharmaceutical market

scholarly journals PHARMACEUTICAL MARKET ASSORTMENT RESEARCH OF DRUGS FOR VAGINAL USE WITH PROBIOTIC MEDICINES DETAILING

2021 ◽  
Vol 127 (4) ◽  
pp. 55-67
Author(s):  
Svitlana Aleinyk
Keyword(s):  
Web Sites ◽  
Marketing Research ◽  
Storage Period ◽  
Dosage Forms ◽  
Pharmaceutical Market ◽  
Brand Names ◽  
Solid Dosage Forms ◽  
Solid Dosage ◽  
State Register ◽  
Probiotic Activity

vaginal route delivery of drugs is an integral part of gynaecological diseases treatment including different genesis vulvovaginitis. The aim of this study it to analyze Ukrainian pharmaceutical market assortment of drugs for vaginal use with probiotic medicines determination. The marketing research was conducted with using of analysis, synthesis, comparison, generalization, content-analysis, statistical, graphical methods. The data of State register of medicines (as of June, 30, 2021), register of wholesale dispensing prices for medicines (as of June, 30, 2021), official web-sites LLC «Morion», «Pharmacy.online», «Compendium.online» were used as objects of the study. As a result, it is determined that as of June 30, 2021 142 medicines for vaginal use are registered on Ukrainian pharmaceutical market with dosage forms, active substances doses, condition for dispensing consideration, 100 brand names, 26 international nonproprietary names, 7 synonymous names. Structural ATC-classification analysis has shown that medicines for vaginal use are included in ATC-groups G «Genito urinary system and sex hormones» and D «Dermatologicals» The assortment macrocontour is formed, it demonstrates that 67,2% of drugs for vaginal use are involved in group G01A «Аntiinfectives and antiseptics, excluding combinations with corticosteroids». More than 80% of drugs for vaginal use are registered as solid dosage forms, and almost half of them as suppositories or pessaries. Almost 65% of medicines are foreign, and 3/4 of them contain only active substance, more than 50% are prescription only medicines. For 44,4% drugs for vaginal use the storage period of 3 years (36 months) is determined. Detailing analysis of medicines with probiotic activity has shown assortment deficiency (only 3 brand names are registered). The liquidity coefficients calculations for this brand manes don’t allow to characterize these drugs as economically affordable. The obtained results of this study inform about the domestic drugs for vaginal use with probiotic activity development relevance, especially in pessaries as dominant dosage form on the pharmaceutical market.

scholarly journals ДОСЛІДЖЕННЯ АСОРТИМЕНТУ АНТИГІПЕРТЕНЗИВНИХ ПРЕПАРАТІВ, ЩО ПРЕДСТАВЛЕНІ НА ФАРМАЦЕВТИЧНИХ РИНКАХ УКРАЇНИ ТА ПОЛЬЩІ

2015 ◽  
Author(s):  
Н. Ю. Полуйчак ◽  
М. Б. Демчук ◽  
О. О. Юр'єва ◽  
Т. А. Грошовий
Keyword(s):  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Antihypertensive Drugs ◽  
Antihypertensive Agents ◽  
Renin Angiotensin System ◽  
Pharmaceutical Market ◽  
Channel Blockers ◽  
Angiotensin System ◽  
Pharmaceutical Markets ◽  
State Register

<h2>RESEARCH OF ANTIHYPERTENSIVE MEDICINESʼ ASSORTMENT WHICH ARE PRESENTED IN PHARMACEUTICAL MARKETS OFUKRAINEANDPOLAND</h2><h2>N.Yu. Poluychak, M.B. Demchuk, O.О. Yurуeva<sup>1</sup>, T.A. Groshovyi,</h2><h2>SHEI «TernopilStateMedicalUniversityby I.Ya. Horbachevsky»</h2><h2><sup>1</sup>JSC «Farmak»</h2><h2>Summary. The article analyzes the antihypertensive medicinesʼ assortment which is presented in the pharmaceutical markets ofUkraineandPoland. Assortment policies of pharmaceutical manufacturers of antihypertensive drugs, diuretics, b-adrenergic blockers, calcium antagonists, drugs that affect the renin-angiotensin system are analyzed.</h2><h2>Key words: hypertension, pharmaceutical market ofUkraine, pharmaceutical market ofPoland, antihypertensive medicines.</h2><p> </p><p><strong>Introduction. </strong>Diseases of the cardiovascular system (CAS) are the leader in the structure of morbidity and mortality in the adult population of highly developed countries. Among pathology of CAS the most common is arterial hypertension (AH), which is found in 15-20% of adults in industrialized countries and is recognized as a chronic no communicable disease. Despite the global nature of the prevalence of hypertension, certain regions of the world differ greatly on this indicator. AG has acquired a large spread in the European Region.</p><p>         All classes of antihypertensive agents recommended by the European Society of Cardiology and the Society for AH (2003), US Joint National Committee (7th revision, 2003) and Ukrainian Society of Cardiology (2004) as first-line drugs in the treatment of hypertension, almost equally reduce blood pressure. It is well known that such pharmacological groups that can be used as part of a monotherapy and in combination therapy include the following drugs: diuretics; angiotensin-converting enzyme (ACE) inhibitors; calcium channel blockers; angiotensin II receptor antagonists; β-blockers. The group of second-line drugs is forming alpha 1-blockers; Rauvolfia alkaloids; central α2-agonists; imidazoline receptor agonist drugs.</p><p>         The purpose of this study is to<strong> </strong>study the assortment medicines for the treatment of hypertension, which are available to consumers onUkraine by comparison with an assortment of antihypertensive drugs, which are represented in the pharmaceutical market inPoland.</p><p>         <strong>Methods.</strong> Analysis of the assortment of drugs that are presented in the domestic pharmaceutical market conducted under Ukrainian State Register of medicines. For the study of current state of the Polish market of antihypertensive agents, the Polish State Register of medicines and official website http://pharmindex.pl, http://leki-informacje.pl., is applied.</p><p>         <strong>Results and discussion</strong>. According to the State Register of medicines ofUkraine by January2015, a group of antihypertensive drugs consists of more than 790 drugs. The antihypertensive agentsʼ group represented more than 940 drugs on the Polish pharmaceutical market. According to ATC - classification analyzed following groups: C02 - antihypertensive drugs, C03 - diuretics, C07 - beta blocking agents, C08 - calcium channel blockers, C09 - agents acting on the renin-angiotensin system.</p><p><strong>Conclusions. </strong>The majority of medicines, which are offered on the European markets, are represented in domestic market. The exclusions are the medicines, which contain clopamide, chlortalidone, canreon – from the diuretics group, pindolol and acetebulol – from the β-blockers group, isradipine – from the group of calcium channel blockers, benazepril, cilazapril, trandolapril and imidapril – from angiotensin-converting-enzyme inhibitors group. Assortment of antihypertensive medicines in the market of Poland is represented by combined medicines of benazepril with diuretics, cilazapril with diuretics, ramipril with felodipine, aliskiren with amlodipine, which are absent on the domestic market.</p>

scholarly journals The analysis of prolonged-release drugs at the Ukrainian pharmaceutical market

2021 ◽  
Vol 7 (3) ◽  
pp. 64-72
Author(s):  
K. V. Tarapon ◽  
O. V. Tryhubchak
Keyword(s):  
Nervous System ◽  
Classification System ◽  
Marketing Research ◽  
Dosage Forms ◽  
Pharmaceutical Market ◽  
Prolonged Release ◽  
Scientific Analysis ◽  
Inflammatory Drugs ◽  
Trade Names ◽  
Marketing Methods

Aim. To analyze the range of prolonged-release dosage forms at the Ukrainian pharmaceutical market focusing on the pharmacotherapeutic groups that are insufficiently saturated with prolonged-release drugs, in particular to determine the proportion of non-steroidal anti-inflammatory drugs (NSAIDs). Materials and methods. The research was conducted in accordance with the data of the State Registry of Medicines of Ukraine and the АТС classification system. The methods of scientific analysis, in particular methods of grouping and comparison, marketing methods of analysis were applied. Results. The study of the assortment of prolonged-release drugs registered at the Ukrainian pharmaceutical market has been performed. The structure of the assortment by manufacturer, dosage forms, the АТС classification system has been analyzed. As a result of the study, it has been found that 202 trade names of prolonged-release drugs are registered in Ukraine. Most of them (196 names, 84 %) are medicines of foreign manufacturers. Prolonged-release drugs registered in Ukraine are mostly presented in the form of tablets and capsules, but tablets (72.77 %) are the largest part. The analysis of distribution of prolonged-release drugs by the ATC classification groups has shown that a significant number of prolonged-release drugs belongs to group N – Nervous system (80 trade names), and group C – Cardiovascular system (44 trade names). The share of group M – Musculoskeletal system, in particular prolonged-release NSAIDs, is insignificant (9 trade names). Conclusions. The marketing research of the prolonged-release drugs conducted allowed us to characterize the structure of the assortment of the Ukrainian market by pharmacotherapeutic groups, manufacturers and dosage forms. As a result of the research, the current assortment of prolonged-release NSAIDs has been determined.

scholarly journals The analysis of the pharmaceutical supply with medicines used in insect allergy therapy and approaches to the development of new medicines in the form of a gel for the local treatment

2021 ◽  
Vol 7 (3) ◽  
Author(s):  
T. V. Popova ◽  
A. S. Nemchenko ◽  
H. P Kukhtenko
Keyword(s):  
Medical Care ◽  
System Analysis ◽  
Local Treatment ◽  
Local Therapy ◽  
Scientific Publications ◽  
State Register ◽  
Icd 10 ◽  
Insect Allergy ◽  
The Subject ◽  
Insect Bites

According to the World Allergy Organization, allergies occur in 10 % to 40 % of the world’s population. Currently, the number of such patients in Europe is about 150 million people. It is projected that in the next decade there will be more than 250 million people, 5 % of whom have a predisposition to insect allergies (IA).Aim. To analyze the range of drugs used in the local treatment of IA and approaches to the development of new domestic drugs in the form of a gel.Materials and methods. The scientific publications of domestic and foreign authors, data from official sites on the subject, ICD-10, materials of the State Register of Medicines of Ukraine, directory Compendium, Protocol for medical care for insect allergies, as well as methods of the system analysis, comparison, graphical, analytical and the content analysis were used.Results. The regimen of IA treatment has been studied depending on the severity (mild, moderate, severe, anaphylactic shock), which is given in the Protocol of medical care for insect allergies in accordance with the Order of the Ministry of Health of Ukraine from 03.07.2006 No.432. It is considered that IA is treated with the subgroup “D04A A – Antihistamines for topical application”, which has only 5 drugs (including release forms); among them 80 % of medicines are foreign, 60 % are produced in the form of a gel. It is very insufficient because of the fact that there are consequences of insect bites during the local therapy of children since constant scratching of the bite sites is a threat of infection of wounds and delay their healing.Conclusions. On the example of the pharmaceutical composition in the form of a gel, the expediency for developing new domestic drugs that are available compared to foreign ones for the local therapy in IA, and manifestations of allergic reactions to insect bites has been proven.

Sign in / Sign up

Export Citation Format

Share Document